Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]

D. Oh; A. R. He; S. Qin; L. Chen; T. Okusaka; A. Vogel; J. W. Kim; T. Suksombooncharoen; M. A. Lee; M. Kitano; H. A. Burris; M. Bouattour; S. Tanasa; R. E. Zaucha; A. Avallone; J. E. Cundom; N. Rokutanda; M. Żotkiewicz; G. Cohen; J. W. Valle

doi:10.1016/j.annonc.2023.02.001

Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]

D. Oh, A. R. He, S. Qin, L. Chen, T. Okusaka, A. Vogel, J. W. Kim, T. Suksombooncharoen, M. A. Lee, M. Kitano, H. A. Burris, M. Bouattour, S. Tanasa, R. E. Zaucha, A. Avallone, J. E. Cundom, N. Rokutanda, M. Żotkiewicz, G. Cohen, J. W. Valle

Division of Oncology

Research output: Contribution to journal › Comment/debate

Abstract

The organisers regret that in the original publication the author listing and affiliations were incorrectly given. The correct author listing and affiliations are now given above. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	633
Number of pages	1
Journal	Annals of Oncology
Volume	34
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2023.02.001
State	Published - Jul 2023

Bibliographical note

Publisher Copyright:
© 2023 European Society for Medical Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2023.02.001

Fingerprint

Dive into the research topics of 'Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]'. Together they form a unique fingerprint.

Cite this

Oh, D., He, A. R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Lee, M. A., Kitano, M., Burris, H. A., Bouattour, M., Tanasa, S., Zaucha, R. E., Avallone, A., Cundom, J. E., Rokutanda, N., Żotkiewicz, M., Cohen, G., & Valle, J. W. (2023). Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]. Annals of Oncology, 34(7), 633. https://doi.org/10.1016/j.annonc.2023.02.001

Oh, D. ; He, A. R. ; Qin, S. et al. / Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)” : [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]. In: Annals of Oncology. 2023 ; Vol. 34, No. 7. pp. 633.

@article{e45592b46a08402181406c773049b0ab,

title = "Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]",

abstract = "The organisers regret that in the original publication the author listing and affiliations were incorrectly given. The correct author listing and affiliations are now given above. The authors would like to apologise for any inconvenience caused.",

author = "D. Oh and He, {A. R.} and S. Qin and L. Chen and T. Okusaka and A. Vogel and Kim, {J. W.} and T. Suksombooncharoen and Lee, {M. A.} and M. Kitano and Burris, {H. A.} and M. Bouattour and S. Tanasa and Zaucha, {R. E.} and A. Avallone and Cundom, {J. E.} and N. Rokutanda and M. {\.Z}otkiewicz and G. Cohen and Valle, {J. W.}",

note = "Publisher Copyright: {\textcopyright} 2023 European Society for Medical Oncology",

year = "2023",

month = jul,

doi = "10.1016/j.annonc.2023.02.001",

language = "English",

volume = "34",

pages = "633",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "7",

}

Oh, D, He, AR, Qin, S, Chen, L, Okusaka, T, Vogel, A, Kim, JW, Suksombooncharoen, T, Lee, MA, Kitano, M, Burris, HA, Bouattour, M, Tanasa, S, Zaucha, RE, Avallone, A, Cundom, JE, Rokutanda, N, Żotkiewicz, M, Cohen, G & Valle, JW 2023, 'Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]', Annals of Oncology, vol. 34, no. 7, pp. 633. https://doi.org/10.1016/j.annonc.2023.02.001

Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]. / Oh, D.; He, A. R.; Qin, S. et al.
In: Annals of Oncology, Vol. 34, No. 7, 07.2023, p. 633.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”

T2 - [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]

AU - Oh, D.

AU - He, A. R.

AU - Qin, S.

AU - Chen, L.

AU - Okusaka, T.

AU - Vogel, A.

AU - Kim, J. W.

AU - Suksombooncharoen, T.

AU - Lee, M. A.

AU - Kitano, M.

AU - Burris, H. A.

AU - Bouattour, M.

AU - Tanasa, S.

AU - Zaucha, R. E.

AU - Avallone, A.

AU - Cundom, J. E.

AU - Rokutanda, N.

AU - Żotkiewicz, M.

AU - Cohen, G.

AU - Valle, J. W.

PY - 2023/7

Y1 - 2023/7

N2 - The organisers regret that in the original publication the author listing and affiliations were incorrectly given. The correct author listing and affiliations are now given above. The authors would like to apologise for any inconvenience caused.

AB - The organisers regret that in the original publication the author listing and affiliations were incorrectly given. The correct author listing and affiliations are now given above. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85151475911&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2023.02.001

DO - 10.1016/j.annonc.2023.02.001

M3 - Comment/debate

AN - SCOPUS:85151475911

SN - 0923-7534

VL - 34

SP - 633

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Oh D, He AR, Qin S, Chen L, Okusaka T, Vogel A et al. Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463, (S0923753422043058), (10.1016/j.annonc.2022.10.114)]. Annals of Oncology. 2023 Jul;34(7):633. doi: 10.1016/j.annonc.2023.02.001